Effect of polydeoxyribonucleotide as a potential therapeutic agent to enhance the healing of Crohn’s perianal fistula
Inflammatory Bowel Diseases · 01.08.2026 · 32 (8) · 1471-1480
DOI: 10.1093/ibd/izag047 ↗Kurz gefasst
Fachartikel in der Zeitschrift Inflammatory Bowel Diseases, online erschienen am 11.04.2026. Verfasst von Hyeon Kyeong Kim und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Surgery, College of Medicine, St. Vincent's Hospital, The Catholic University of Korea , Address 93, Jungbu-daero, Paldal-gu, Suwon-si,…. Hauptthemen laut MEDLINE: Rectal Fistula, Crohn Disease, Wound Healing, Polydeoxyribonucleotides. Die Arbeit nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
The treatment of Crohn’s perianal fistula remains challenging owing to its recurrent nature and resistance to complete healing. This study aimed to assess the postoperative outcomes, including fistula closure rates, following Crohn’s perianal fistula surgery, with and without polydeoxyribonucleotide administration.
Methods
A retrospective review was conducted on patients who underwent fistula closure operations for Crohn’s perianal fistula at a single tertiary center in Seoul, Korea, between January 2018 and June 2024. Patients were divided into two groups based on the use of local polydeoxyribonucleotide (PDRN) injections during fistula closure operations, and clinical variables and postoperative outcomes were compared between the groups.
Results
Among the 47 patients, 21 (44.7%) were assigned to the PDRN group and 26 (55.3%) were assigned to non-PDRN group. Baseline characteristics between the two groups showed no significant difference. During the mean follow-up of 30.4 months, patients in the PDRN group demonstrated a significantly higher complete fistula closure rate (70.0% vs 26.9% at 6 months, and 83.3% vs 46.2% at 12 months; P = .005), and a shorter time from surgery to complete closure (3.3 ± 2.6 months vs 5.9 ± 3.8 months; P = .044), compared with the non-PDRN group. Multivariate analysis revealed PDRN as an independent factor significantly associated with Crohn’s perianal fistula closure (HR 2.336; 95% CI, 1.092-4.997, P = .029).
Conclusions
PDRN is a potential therapeutic agent that presents a viable option for Crohn’s perianal fistula surgery, improving complete fistula closure rate through a safe, cost-effective, and relatively simple procedure.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Surgery, College of Medicine, St. Vincent's Hospital, The Catholic University of Korea , Address 93, Jungbu-daero, Paldal-gu, Suwon-si, Gyeonggi-do, South Korea.
- Division of Colon and Rectal Surgery, Department of Surgery, University of Ulsan College of Medicine, Asan Medical Center , Address 88 Olympic-ro 43-gil, Songpa-gu, Seoul 05505, South Korea.
ORCID-Profile: Hyeon Kyeong Kim, Yong Sik Yoon, Jong Lyul Lee, Eun Jung Park, Min Hyun Kim, Young Il Kim, Chan Wook Kim, In Ja Park, Seok-Byung Lim, Chang Sik Yu
Zitieren
APA
Kim, H. K., Yoon, Y. S., Lee, J. L., Park, E. J., Kim, M. H., Kim, Y. I., Kim, C. W., Park, I. J., Lim, S. B., & Yu, C. S. (2026). Effect of polydeoxyribonucleotide as a potential therapeutic agent to enhance the healing of Crohn’s perianal fistula. Inflammatory Bowel Diseases, 32(8), 1471-1480. https://doi.org/10.1093/ibd/izag047
Vancouver
Kim HK, Yoon YS, Lee JL, Park EJ, Kim MH, Kim YI, et al. Effect of polydeoxyribonucleotide as a potential therapeutic agent to enhance the healing of Crohn’s perianal fistula. Inflammatory Bowel Diseases. 2026;32(8):1471-1480. doi:10.1093/ibd/izag047
BibTeX
@article{Kim2026,
author = {Kim, Hyeon Kyeong and Yoon, Yong Sik and Lee, Jong Lyul and Park, Eun Jung and Kim, Min Hyun and Kim, Young Il and Kim, Chan Wook and Park, In Ja and Lim, Seok-Byung and Yu, Chang Sik},
title = {Effect of polydeoxyribonucleotide as a potential therapeutic agent to enhance the healing of Crohn’s perianal fistula},
journal = {Inflammatory Bowel Diseases},
year = {2026},
volume = {32},
number = {8},
pages = {1471--1480},
doi = {10.1093/ibd/izag047}
}
EUVIMED